Cellectis S.A.
Business
Cellectis S.A. is a clinical-stage biotechnology company developing gene-edited cell therapies using proprietary TALEN nuclease technology. The company's lead product candidates are allogeneic chimeric antigen receptor T-cells (UCART) designed as off-the-shelf immunotherapies for hematologic cancers and gene therapy products for genetic diseases. Cellectis operates through internal development of UCART candidates and licensing agreements with AstraZeneca, Allogene, Servier, and Iovance. The company manufactures products at facilities in Raleigh, North Carolina and Paris, France, and markets to oncology and gene therapy indications globally.
Summary from 20-F filed 2026-03-20
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-67.59M |
| Total assets | $324.72M |
| Total liabilities | $248.82M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Cellectis S.A.'s CIK number?
Cellectis S.A.'s SEC CIK number is 0001627281 (1627281). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Cellectis S.A.'s SEC filings?
All of Cellectis S.A.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.